EUVIMEDEUVIMED entdecken
Crossref

ATAGI Targeted Review 2023: Vaccination for prevention of influenza in Australia

Chisato Imai, Sanjay Jayasinghe, Jocelynne McRae, Jean Li-Kim-Moy, Clayton Chiu, Kristine Macartney, Penelope Burns, Kristy Cooper, Allen C Cheng, Katherine Gibney, Michelle Giles, Cheryl Jones und 4 weitere

Communicable Diseases Intelligence · 2024

DOI: 10.33321/cdi.2024.48.25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2024. Verfasst von Chisato Imai und 15 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Immunisation Research and Surveillance, The University of Sydney and The Children's Hospital at Westmead, Sydney, Australia. Hauptthemen laut MEDLINE: COVID-19, Influenza Vaccines, Influenza, Human, Immunization Programs. Die Arbeit wurde bisher 4-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Annual seasonal influenza epidemics cause substantial disease and economic burden worldwide. During the coronavirus disease 2019 (COVID-19) pandemic in 2020 and 2021, influenza activity significantly declined. However, influenza resurged in Australia following the relaxation of non-pharmaceutical interventions, with increased influenza virus circulation in early 2022 coinciding with the SARS-CoV-2 Omicron BA.2 variant wave. Together with other respiratory virus diseases, these disease impacts on the Australian population and healthcare system have re-emphasised the importance of influenza vaccination and control. We aim to provide an overview of the current seasonal influenza vaccination program in Australia and summarise evidence and considerations underpinning potential future immunisation strategies. Influenza causes disproportionately higher morbidity and mortality in young children and older adults. Other populations at elevated risk from influenza include Aboriginal and Torres Strait Islander peoples, pregnant women, and people with certain underlying medical conditions. All Australians aged ≥ 6 months are recommended to receive influenza vaccine every year. The National Immunisation Program (NIP) provides free vaccine for eligible at-risk populations. While approximately 70% of older adults had received influenza vaccine in 2022, coverage in other age groups remains suboptimal. There are several key unmet needs and challenges, but also potential strategies for enhancing the influenza vaccination program in Australia. Improved monitoring and evaluation, including the use of relevant linked datasets for such purposes, is imperative to better understand variations in coverage and vaccination impact in specific populations. Adoption of evidence-based strategies, such as culturally appropriate resources that consider the characteristics of diverse Australian populations, may also help to achieve higher vaccine coverage rates. Additionally, greater vaccine uptake across the population could be facilitated by expanding the NIP-eligible population where cost-effective, and adopting the use of more effective and different types of vaccines when available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Influenza VaccinesInfluenza, HumanImmunization ProgramsHumansAustraliaSARS-CoV-2VaccinationAdultFemaleChildAgedAdolescentChild, PreschoolInfantMiddle AgedYoung AdultAnnual Reports as TopicPregnancyMaleAustralian Aboriginal and Torres Strait Islander Peoples

Stichwörter der Autor:innen

Australian Technical Advisory Group on Immunisation (ATAGI)National Immunisation Technical Advisory Group (NITAG)immunisation programsinfluenzainfluenza vaccineprevention and control

Substanzen

Influenza Vaccines

Autor:innen und Institutionen

  • National Centre for Immunisation Research and Surveillance, The University of Sydney and The Children's Hospital at Westmead, Sydney, Australia.
  • Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
  • Australian Technical Advisory Group on Immunisation, Department of Health and Aged Care, Australian Government, Canberra, Australian Capital Territory, Australia.
  • Academic Unit of General Practice, College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory, Australia.
  • Department of General Practice, School of Medicine, Western Sydney University, Sydney, Australia.
  • Monash Infectious Diseases, Monash Health; School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.

Zitieren

APA

Imai, C., Jayasinghe, S., McRae, J., Li-Kim-Moy, J., Chiu, C., Macartney, K., Burns, P., Cooper, K., Cheng, A. C., Gibney, K., Giles, M., Jones, C., Korman, T., Liu, B., Crawford, N. W., & Australian Technical Advisory Group on Immunisation (ATAGI) (2024). ATAGI Targeted Review 2023: Vaccination for prevention of influenza in Australia. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2024.48.25

Vancouver

Imai C, Jayasinghe S, McRae J, Li-Kim-Moy J, Chiu C, Macartney K, et al. ATAGI Targeted Review 2023: Vaccination for prevention of influenza in Australia. Communicable Diseases Intelligence. 2024. doi:10.33321/cdi.2024.48.25

BibTeX
@article{Imai2024,
  author = {Imai, Chisato and Jayasinghe, Sanjay and McRae, Jocelynne and Li-Kim-Moy, Jean and Chiu, Clayton and Macartney, Kristine and Burns, Penelope and Cooper, Kristy and Cheng, Allen C and Gibney, Katherine and Giles, Michelle and Jones, Cheryl and Korman, Tony and Liu, Bette and Crawford, Nigel W and Australian Technical Advisory Group on Immunisation (ATAGI), Australian Technical Advisory Group on Immunisation (ATAGI)},
  title = {ATAGI Targeted Review 2023: Vaccination for prevention of influenza in Australia},
  journal = {Communicable Diseases Intelligence},
  year = {2024},
  doi = {10.33321/cdi.2024.48.25}
}
Kostenlos starten →